Organovo (ONVO) Reports In-Line Q4 EPS, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019
May 31, 2018 4:05 PM EDT- Lead Investigational New Drug (IND) program for Alpha-1-antitrypsin deficiency (A1AT) received FDAs orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019
- Second IND-track program in orphan liver disease expected to be nominated in fiscal 2019
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO) (Organovo), Â a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today reported its fiscal fourth-quarter and full-year 2018 financial results and announced its key... More
